Published in Circulation on November 24, 2003
Thrombotic, Inflammatory & Gene Markers of CVD in Women | NCT00006539
Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health (2007) 1.88
The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens (2010) 1.86
Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep (2012) 1.45
Association Between Low-Grade Systemic Inflammation and Type 2 Diabetes Mellitus Among Men and Women from the ATTICA Study. Rev Diabet Stud (2007) 1.17
Extreme sleep durations and increased C-reactive protein: effects of sex and ethnoracial group. Sleep (2013) 1.16
Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin Immunol (2009) 1.09
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens (2011) 1.03
Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int (2014) 1.01
Association between dietary pattern and serum C-reactive protein in Japanese men and women. J Epidemiol (2011) 1.01
The pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol (2009) 0.99
Elevated blood pressure, race/ethnicity, and C-reactive protein levels in children and adolescents. Pediatrics (2008) 0.96
Role of surrogate markers of atherosclerosis in clinical and subclinical thyroidism. Int J Endocrinol (2012) 0.95
Dual opposing roles of adaptive immunity in hypertension. Eur Heart J (2014) 0.95
Coupling of Fcγ receptor I to Fcγ receptor IIb by SRC kinase mediates C-reactive protein impairment of endothelial function. Circ Res (2011) 0.90
Early detection and management of the high-risk patient with elevated blood pressure. Vasc Health Risk Manag (2008) 0.90
Periodontal disease and risk of atherosclerotic coronary heart disease. Odontology (2009) 0.89
Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: a longitudinal study. Clin Chem (2009) 0.85
Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury. Arch Phys Med Rehabil (2008) 0.84
Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. Hypertens Res (2011) 0.84
Dietary antioxidant capacity is associated with improved serum antioxidant status and decreased serum C-reactive protein and plasma homocysteine concentrations. Eur J Nutr (2013) 0.84
Psychosocial stress and cardiovascular diseases. Postgrad Med J (2005) 0.83
Reduction of C-reactive protein and the use of anti-hypertensives. Vasc Health Risk Manag (2007) 0.82
Systemic inflammation and circadian rhythm of cardiac autonomic modulation. Auton Neurosci (2011) 0.82
High-sensitivity C-reactive protein: an independent risk factor for left ventricular hypertrophy in patients with lupus nephritis. J Biomed Biotechnol (2010) 0.81
C-reactive protein is an independent predictor for carotid artery intima-media thickness progression in asymptomatic younger adults (from the Bogalusa Heart Study). BMC Cardiovasc Disord (2011) 0.81
Neighborhoods and systemic inflammation: high CRP among legal and unauthorized Brazilian migrants. Health Place (2012) 0.81
Increased Hs-CRP/adiponectin ratio is associated with increase carotid intima-media thickness. Lipids Health Dis (2014) 0.81
Pleiotropy among common genetic loci identified for cardiometabolic disorders and C-reactive protein. PLoS One (2015) 0.80
Depression and the Link with Cardiovascular Disease. Front Psychiatry (2016) 0.80
Predictors of cardiovascular autonomic neuropathy in patients with type 1 diabetes. Front Endocrinol (Lausanne) (2014) 0.79
Efect of periodontal disease and non surgical periodontal treatment on C-reactive protein. Evaluation of type 1 diabetic patients. Med Oral Patol Oral Cir Bucal (2012) 0.79
Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy. J Diabetes Investig (2012) 0.78
Relationships between serial childhood adiposity measures and adult blood pressure: The Fels longitudinal study. Am J Hum Biol (2010) 0.77
Comparison of inflammatory markers in non-dipper hypertension vs. dipper hypertension and in normotensive individuals: uric acid, C-reactive protein and red blood cell distribution width readings. Postepy Kardiol Interwencyjnej (2014) 0.77
E-selectin gene polymorphism (A561C) and essential hypertension. Meta-analysis in the Chinese population. Herz (2014) 0.77
Atherothrombosis in South asians: implications of atherosclerotic and inflammatory markers. Open Cardiovasc Med J (2010) 0.77
Understanding mechanisms of hypertension in systemic lupus erythematosus. Ther Adv Cardiovasc Dis (2016) 0.77
The relationship between serum levels of hs-CRP and coronary lesion severity. Clujul Med (2016) 0.76
An updated concept for left ventricular hypertrophy risk in hypertension. Ochsner J (2009) 0.76
Is there any relationship between RDW levels and atrial fibrillation in hypertensive patient? Afr Health Sci (2014) 0.75
Prognostic Importance of C-Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study. J Am Heart Assoc (2016) 0.75
Functional analysis of UMOD gene and its effect on inflammatory cytokines in serum of essential hypertension patients. Int J Clin Exp Pathol (2015) 0.75
Randomised controlled trial of a 12 week yoga intervention on negative affective states, cardiovascular and cognitive function in post-cardiac rehabilitation patients. BMC Complement Altern Med (2014) 0.75
Relationship of high-sensitive C-reactive protein with cardiovascular risk factors, clinical presentation and angiographic profile in patients with acute coronary syndrome: an Indian perspective. Indian Heart J (2013) 0.75
Social support moderates the relationship between sleep and inflammation in a population at high risk for developing cardiovascular disease. Psychophysiology (2015) 0.75
Relevance of prehypertension as a diagnostic category in asymptomatic adults. Einstein (Sao Paulo) (2013) 0.75
Modulatory Effect of Inflammation on Blood Pressure Reduction via Therapeutic Lifestyle Change. Ochsner J (2009) 0.75
Time-cumulated blood pressure exposure and incident impairment of glucose tolerance and diabetes mellitus. BMC Cardiovasc Disord (2017) 0.75
Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. Am J Hypertens (2016) 0.75
Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside. Biologics (2008) 0.75
Role of plasma adiponectin /C-reactive protein ratio in obesity and type 2 diabetes among African Americans. Afr Health Sci (2017) 0.75
Short-term changes on C-reactive protein (CRP) levels after non-surgical periodontal treatment in systemically healthy individuals. Clin Oral Investig (2016) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Inflammation and atherosclerosis. Circulation (2002) 20.77
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Progress and challenges in translating the biology of atherosclerosis. Nature (2011) 9.41
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med (2009) 7.62
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med (2012) 5.98
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med (2007) 5.95
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA (2005) 5.74
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28
Physical activity and weight gain prevention. JAMA (2010) 5.27
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ (2009) 4.98
C-reactive protein and the risk of incident colorectal cancer. JAMA (2004) 4.94
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med (2004) 4.92
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes (2004) 4.67
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation (2004) 4.58
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47
Association between a literature-based genetic risk score and cardiovascular events in women. JAMA (2010) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Prevalence of dry eye syndrome among US women. Am J Ophthalmol (2003) 4.46
Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clin Chem (2007) 4.45
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
Inflammation as a cardiovascular risk factor. Circulation (2004) 4.26
Association between C-reactive protein and age-related macular degeneration. JAMA (2004) 4.16
Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA (2004) 4.04
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov (2005) 3.92
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation (2005) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA (2004) 3.69
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61